Daily Roundup

XRF.ASX HUB.ASX PME.ASX BOT.ASX AX1.ASX

Strong Quarter for XRF Scientific

XRF Scientific Ltd has reported a positive March 2025 quarter, with revenue of $13.9 million and Profit Before Tax of $3.4 million. The company saw strong international sales development, particularly in Asia, the Americas, and Europe, driving growth across all divisions.

Consumable sales remained robust at $4.4 million, with the mining industry continuing to be the main driver. Capital equipment product sales were $4.5 million, with steady incoming machine orders. Precious metals sales were $4.9 million, affected by product mix but still generating strong margins.

Looking ahead, XRF will focus on growing international sales, new product developments, and M&A opportunities during the June 2025 quarter.

HUB24 Delivers Record Inflows

HUB24 Limited reported a standout Q3 FY25, with record Platform net inflows of $4.9 billion, up 39% on the prior year. Total Funds Under Administration (FUA) reached $124.1 billion, comprising $102.5 billion in Platform FUA and $21.6 billion in Portfolio, Administration and Reporting Services (PARS) FUA.

The HUB24 Platform was ranked first for quarterly and annual net inflows, and the company was recognized for its innovative products and solutions, including winning several industry awards.

While recent market volatility has the potential to impact FUA, HUB24 remains confident in its growth outlook, driven by its market-leading offerings and strong customer relationships.

Pro Medicus Partners with UCSF on AI Research

Pro Medicus Limited has signed a multi-year research collaboration agreement with the University of California, San Francisco (UCSF) to leverage the Visage AI Accelerator platform for artificial intelligence research and development.

The partnership will facilitate the development and commercialization of innovative AI solutions, with the potential to improve patient outcomes in the field of healthcare imaging. Pro Medicus sees AI as a significant growth opportunity, and this collaboration with UCSF is a key part of the company's AI strategy.

Botanix Raises $40 Million to Accelerate Sofdra Rollout

Botanix Pharmaceuticals has secured $40 million in a capital raising to fund the expansion of sales, marketing, and support activities for its FDA-approved product Sofdra, used to treat primary axillary hyperhidrosis.

The company has seen strong early sales performance, with over 500 new patients per week and more than 1,500 prescribers writing Sofdra prescriptions since the sales force launched. Botanix expects to see continued growth in new patient arrivals, prescriber numbers, and refill rates for Sofdra in the coming quarters.

Accent Group Strikes Strategic Deal with Frasers Group

Accent Group Limited has announced a long-term strategic relationship with Frasers Group plc to launch and operate the Sports Direct retail business in Australia and New Zealand.

Accent will be granted the rights to launch and operate Sports Direct (including online) in the region for an initial 25-year term, with plans for an initial roll-out of at least 50 stores over the next 6 years, and ultimately an opportunity for 100 plus stores.

Frasers will also increase its shareholding in Accent to 19.57% and provide access to its owned brand portfolio for Accent's stores. Accent has also entered a new 3-year employment agreement with CEO Daniel Agostinelli.